Daxor Corporation (DXR)
NasdaqCM
Fundamentals
Valuation and ratings
Daxor Corporation trades at USD10.45. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Super investor ownership
1 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$270.9K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own DXR?
1 of the institutions we track reported a position in DXR in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for DXR, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.